Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

A Deep Learning-Based Pathomics Methodology for Quantifying and Characterizing Nucleated Cells in the Bone Marrow Microenvironment

Spencer Krichevsky, Madhu M Ouseph, Yuwei Zhang, Ghaith Abu-Zeinah, Joseph M. Scandura, Rajarsi Gupta

Blood (2023) 142 (Supplement 1): 2294.

https://doi.org/10.1182/blood-2023-191272

Published: 2023

Journal Articles

Using Machine Learning to Predict Near-Term Thrombosis Risk in Patients with Polycythemia Vera

Spencer Krichevsky, Ghaith Abu-Zeinah, Katie Erdos, Joseph M. Scandura

Blood (2023) 142 (Supplement 1): 3186.

https://doi.org/10.1182/blood-2023-190684

Published: 2023

Journal Articles

Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV

Ghaith Abu-Zeinah, Spencer Krichevsky, Katie Erdos, Richard T. Silver, Joseph Scandura

Blood (2022) 140 (Supplement 1): 3961–3962.

https://doi.org/10.1182/blood-2022-170893

Published: 2022

Journal Articles

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Blood (2021) 138 (Supplement 1): 2583.

https://doi.org/10.1182/blood-2021-150561

Published: 2021

Journal Articles

A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera (PV) Patients

Ghaith Abu-Zeinah, Spencer Krichevsky, Richard T. Silver, Elwood Taylor, III, Douglas Tremblay, Andrew Srisuwananukorn, John Mascarenhas, Joseph Scandura

Blood (2021) 138 (Supplement 1): 3619.

https://doi.org/10.1182/blood-2021-149098

Published: 2021

Journal Articles

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Ghaith Abu-Zeinah, MD, Spencer Krichevsky, BS, Tatiana Cruz, MD, Gabriela Hoberman, BA, Niamh Savage, BA, Ellen Ritchie, MD, Joseph Scandura, MDPhD, Richard T. Silver, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141796

Published: 2020

Journal Articles

Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3

Nicole Mollé, Spencer Krichevsky, Pouneh Kermani, Richard T. Silver, Ellen Ritchie, Joseph M. Scandura

Blood (2020) 135 (13): 1062–1066.

https://doi.org/10.1182/blood.2019003050

Published: 2020

Includes: Supplemental data

Journal Articles

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Spencer Krichevsky, BS, Ghaith Abu Zeinah, MD, Claudia Sosner, BA, Diana Jaber, BA, Niamh Savage, BA, Gabriela Hoberman, BA, Ellen K. Ritchie, MD, Andrew I. Schafer, MD, Richard T. Silver, MD, Joseph Scandura, MD PhD

Blood (2019) 134 (Supplement_1): 1664.

https://doi.org/10.1182/blood-2019-131605

Published: 2019

Journal Articles

Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms

Pinkal Desai, MDMPH, Niamh Savage, BA, Spencer Krichevsky, BS, Tania Curcio, Sangmin Lee, MD, Michael B. Samuel, MD, Ellen K. Ritchie, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 1666.

https://doi.org/10.1182/blood-2019-127663

Published: 2019

Journal Articles

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Ghaith Abu Zeinah, MD, Spencer Krichevsky, BS, Diana Jaber, BA, Niamh Savage, BA, Claudia Sosner, BA, Gabriela Hoberman, BA, Ellen K. Ritchie, MD, Andrew I. Schafer, MD, Joseph Scandura, MD PhD, Richard T. Silver, MD

Blood (2019) 134 (Supplement_1): 2942.

https://doi.org/10.1182/blood-2019-130265

Published: 2019

Journal Articles

Use of Pegylated Interferon in Six Pediatric Patients with Myeloproliferative Neoplasms

Nicole Kucine, MD, Shayla Bergmann, MD, Spencer Krichevsky, BS, Devin Jones, MS, Michael E. Rytting, MD, Linda Resar, MD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 4194.

https://doi.org/10.1182/blood-2019-124023

Published: 2019

Journal Articles

Acute Myeloid Leukemia (AML) with Somatic Mutations in PTPN11 Is Associated with Treatment Resistance and Poor Overall Survival

Justin D. Kaner, MD, Nuria Mencia-Trinchant, PhD, Ariel Schaap, MD, Gail J. Roboz, MD, Sangmin Lee, MD, Pinkal Desai, MD MPH, Michael Samuel, MD, Spencer Krichevsky, BS, Idongessit Udoyen, Duane C. Hassane, PhD, Monica L. Guzman, PhD, Ellen K. Ritchie, MD

Blood (2018) 132 (Supplement 1): 2760.

https://doi.org/10.1182/blood-2018-99-110319

Published: 2018

Journal Articles

Ruxolitinib Can Lead to Weight Gain in Patients with Myeloproliferative Neoplasms By Uncoupling Feeding from Central Leptin Signaling Via JAK2/STAT3

Spencer Krichevsky, BS, Pouneh Kermani, PhD, Nicole Molle, BS, Richard T. Silver, MD, Andrew I. Schafer, MD, Ellen K. Ritchie, MD, Joseph Scandura, MD PhD

Blood (2018) 132 (Supplement 1): 4284.

https://doi.org/10.1182/blood-2018-99-119542

Published: 2018

Journal Articles

A Clinical Review of the Co-Occurrence of Myeloproliferative and Lymphoproliferative Neoplasms

Spencer Krichevsky, BS, Erica B Bhavsar, BS, Richard R. Furman, MD, Ruben Niesvizky, MD, Ellen K. Ritchie, MD, Giorgio Inghirami, MD, Joseph Scandura, MD PhD

Blood (2018) 132 (Supplement 1): 4285.

https://doi.org/10.1182/blood-2018-99-120322

Published: 2018

Journal Articles

Development of an Automated Tool for Assessing Response in Patients with Polycythemia Vera

Evan Sholle, MS, Spencer Krichevsky, BS, Joseph Scandura, MD PhD, Claudia Sosner, BA, Niamh Savage, BA, Thomas R Campion, Jr., PhD

Blood (2018) 132 (Supplement 1): 5462.

https://doi.org/10.1182/blood-2018-99-119628

Published: 2018

Journal Articles

Initial Therapy of Polycythemia Vera (PV) with Interferon Alfa (rIFNa) Compared to Hydroxyurea (HU) or Phlebotomy Only (PHL-O) Is Associated with a Lower Risk of Secondary Myelofibrosis

Ghaith Abu-Zeinah, MD, Spencer Krichevsky, BS, Claudia Sosner, BA, Niamh Savage, BA, Joseph Scandura, MD PhD, Richard T. Silver, MD

Blood (2018) 132 (Supplement 1): 4316.

https://doi.org/10.1182/blood-2018-99-115520

Published: 2018

Journal Articles

Myeloproliferative Neoplasm (MPN) Driver Mutations Are Enriched during Hematopoietic Stem Cell Differentiation in Patterns That Correlate with Clinical Phenotype and Treatment Response

Ghaith Abu-Zeinah, MD, Silvana Di Giandomenico, PhD, Claudia Sosner, BA, Niamh Savage, BA, Spencer Krichevsky, BS, Ellen K. Ritchie, MD, Pouneh Kermani, PhD, Richard T. Silver, MD, Joseph Scandura, MD PhD

Blood (2018) 132 (Supplement 1): 4317.

https://doi.org/10.1182/blood-2018-99-117744

Published: 2018

Journal Articles

Pulmonary Hypertension Independently Shortens Survival of Patients with Myeloproliferative Neoplasms

Jiwon Kim, MD, Spencer Krichevsky, BS, Neil K Mehta, MD, Sara Rodriguez-Diego, MD, Meridith P Pollie, BS, Richard T Silver, MD, Andrew I Schafer, MD, Ellen K Ritchie, MD, Mia Wiese, BS, Claudia Sosner, BA, Evelyn M Horn, MD, Richard B Devereux, MD, Jonathan W Weinsaft, MD, Joseph Scandura, MDPhD

Blood (2017) 130 (Supplement 1): 324.

https://doi.org/10.1182/blood.V130.Suppl_1.324.324

Published: 2017

Journal Articles

Critical Evaluation of Who 2016 Criteria for the Diagnosis of Polycythemia Vera: Distinction from JAK2V617+ Essential Thrombocythemia

Richard T Silver, MD, Spencer Krichevsky, BS

Blood (2017) 130 (Supplement 1): 4181.

https://doi.org/10.1182/blood.V130.Suppl_1.4181.4181

Published: 2017

Journal Articles

Incidence of Infections and Second Cancers in Philadelphia Chromosome-Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib

Ellen K Ritchie, MD, Spencer Krichevsky, BS, Gail J. Roboz, MD, Richard T Silver, MD, Andrew I Schafer, MD, Joseph Scandura, MDPhD, Pinkal Desai, MD MPH, Sangmin Lee, MD, Michael Samuel, MD

Blood (2017) 130 (Supplement 1): 2910.

https://doi.org/10.1182/blood.V130.Suppl_1.2910.2910

Published: 2017

NARROW

A Deep Learning-Based Pathomics Methodology for Quantifying and Characterizing Nucleated Cells in the Bone Marrow Microenvironment

Using Machine Learning to Predict Near-Term Thrombosis Risk in Patients with Polycythemia Vera

Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera (PV) Patients

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Use of Pegylated Interferon in Six Pediatric Patients with Myeloproliferative Neoplasms

Acute Myeloid Leukemia (AML) with Somatic Mutations in PTPN11 Is Associated with Treatment Resistance and Poor Overall Survival

Ruxolitinib Can Lead to Weight Gain in Patients with Myeloproliferative Neoplasms By Uncoupling Feeding from Central Leptin Signaling Via JAK2/STAT3

A Clinical Review of the Co-Occurrence of Myeloproliferative and Lymphoproliferative Neoplasms

Development of an Automated Tool for Assessing Response in Patients with Polycythemia Vera

Initial Therapy of Polycythemia Vera (PV) with Interferon Alfa (rIFNa) Compared to Hydroxyurea (HU) or Phlebotomy Only (PHL-O) Is Associated with a Lower Risk of Secondary Myelofibrosis

Myeloproliferative Neoplasm (MPN) Driver Mutations Are Enriched during Hematopoietic Stem Cell Differentiation in Patterns That Correlate with Clinical Phenotype and Treatment Response

Pulmonary Hypertension Independently Shortens Survival of Patients with Myeloproliferative Neoplasms

Critical Evaluation of Who 2016 Criteria for the Diagnosis of Polycythemia Vera: Distinction from JAK2V617+ Essential Thrombocythemia

Incidence of Infections and Second Cancers in Philadelphia Chromosome-Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only